K. Rene Ward
Associate Director, Public Relations and Internal Communications
3902 Gene Field Road
St. Joseph, Missouri 64506
Changes impact company’s pet, cattle and equine business units
Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces changes to the sales and marketing leadership of its pet, cattle and equine business segments. The changes, effective May 1, 2012, are designed to reinforce the leadership of the company’s domestic sales and marketing organizations today and for the future.
As part of the announced changes, Colin Meyers will assume the role of executive director of the pet business; Steve Boren will assume the role of executive director for the company’s cattle business; and Matt Musselman will lead the equine business unit as executive director.
Tim Bettington, vice president of sales and marketing for BIVI, says the appointments will better position the company to take advantage of increased business opportunities in their respective market segments. “Colin, Steve and Matt were selected for their extensive sales and marketing management experience and professionalism in leading these important BIVI business units moving forward,” Bettington says. “With these appointments, we are well positioned to meet the needs of our customers and capitalize on future market opportunities.”
Bettington, who was appointed to his current position in March, will continue to lead the swine business unit. In addition, the National Account Management team also will report to him.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.